Gastritis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Gastritis - Pipeline Review, H1 2016', provides an overview of the Gastritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Gastritis - The report reviews pipeline therapeutics for Gastritis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Gastritis therapeutics and enlists all their major and minor projects - The report assesses Gastritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Gastritis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Gastritis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gastritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Gastritis Overview 7 Therapeutics Development 8 Pipeline Products for Gastritis - Overview 8 Gastritis - Therapeutics under Development by Companies 9 Gastritis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Gastritis - Products under Development by Companies 13 Gastritis - Companies Involved in Therapeutics Development 14 BCWorld Pharm Co. Ltd. 14 Daewon Pharm Co. Ltd. 15 Recce Limited 16 RedHill Biopharma Ltd. 17 Gastritis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 24 Drug Profiles 25 BCWPA-001 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 DW-3101 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 netazepide - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ondansetron hydrochloride CR - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 PMKS-005 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 RECCE-327 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Gastritis - Recent Pipeline Updates 33 Gastritis - Dormant Projects 38 Gastritis - Product Development Milestones 39 Featured News & Press Releases 39 Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 39 Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 40 Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Number of Products under Development for Gastritis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Gastritis - Pipeline by BCWorld Pharm Co. Ltd., H1 2016 14 Gastritis - Pipeline by Daewon Pharm Co. Ltd., H1 2016 15 Gastritis - Pipeline by Recce Limited, H1 2016 16 Gastritis - Pipeline by RedHill Biopharma Ltd., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 24 Gastritis Therapeutics - Recent Pipeline Updates, H1 2016 33 Gastritis - Dormant Projects, H1 2016 38
List of Figures
Number of Products under Development for Gastritis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Targets, H1 2016 19 Number of Products by Stage and Targets, H1 2016 19 Number of Products by Mechanism of Actions, H1 2016 21 Number of Products by Stage and Mechanism of Actions, H1 2016 21 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Stage and Molecule Types, H1 2016 24
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.